image
mobile_image
eyebrow
headline
Live Longer. It’s Possible.
content
buttons
disclaimer
eyebrow
headline
VYNDAMAX helps people with transthyretin cardiac amyloidosis (ATTR-CM) live longer
headline2
content
- VYNDAMAX* was studied in the “Tafamidis in Transthyretin Amyloidosis Cardiomyopathy Clinical Trial” (known as ATTR-ACT)
- The study tested if VYNDAMAX could help people with ATTR-CM live longer and reduce hospitalizations due to heart problems compared to placebo
- The study also tested the impact of VYNDAMAX on quality of life and ability to function
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
*The clinical studies of VYNDAQEL® (a different form of tafamidis) supported the approval of VYNDAMAX. Both drugs contain the same active ingredient.
Subheader
How was VYNDAMAX studied?
The safety and efficacy of VYNDAMAX were studied in a 30-month clinical study of 441 adult patients with wild-type or hereditary ATTR-CM.
- The VYNDAMAX study primarily focused on the reduction of death and heart-related hospitalizations, as well as safety
- VYNDAMAX was also assessed on other aspects of ATTR-CM, including walking distance (6-Minute Walk Test) and health-related quality of life
- Efficacy and safety were determined by comparing patients treated with VYNDAMAX (n=264), with patients who did not take VYNDAMAX (placebo) (n=177)
- Patients were evaluated every 6 months for a total of 30 months
image
Mobile_image
eyebrow
headline
VYNDAMAX was proven to help people live longer
subheadline
content
After 2 1/2 YEARS more people were alive taking VYNDAMAX than placebo
buttons
content2
disclaimer
Image_disclaimer
Brightcove_video_id
Brightcove_account_id
image
Mobile_image
eyebrow
headline
VYNDAMAX was proven to reduce hospitalizations for heart problems
subheadline
content
In the study, patients taking VYNDAMAX had fewer heart-related hospitalizations than those in the placebo group
buttons
content2
disclaimer
Image_disclaimer
Brightcove_video_id
Brightcove_account_id
eyebrow
headline
Health-related quality-of-life measures†
subheadline
In a 2.5-year clinical study, compared to those not on treatment (placebo group), people taking VYNDAMAX reported:
content
disclaimer
†At the end of the 30-month study compared to people taking a placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to measure health-related quality of life. Patients in the VYNDAMAX and placebo groups had worse KCCQ overall summary scores at month 30 than at the start of the study.
Buttons
icon
headline
Better quality of life
content
(mental health status, enjoyment of life)
disclaimer
Buttons
icon
headline
Fewer heart-related symptoms
content
(shortness of breath, fatigue, swollen feet or ankles)
disclaimer
Buttons
icon
headline
More comfort performing daily activities
content
(ability to perform social and physical activities)
disclaimer
Buttons
icon
headline
While there's no cure today, VYNDAMAX slows down ATTR-CM
subheadline
Remember that even if you don’t feel it working, always take VYNDAMAX as prescribed. It’s important to tell your doctor how you are feeling.
content
disclaimer
buttons
eyebrow
headline
Heart function and exercise capacity were measured in patients taking VYNDAMAX
headline2
content
The 6-Minute Walk Test (6MWT) measured heart function and exercise capacity.
At 30 months, people who took VYNDAMAX were able to walk a significant 83 yards farther (almost the length of a football field) on average than people who did not take VYNDAMAX (placebo).‡
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
‡Patients in the VYNDAMAX and placebo groups had worse 6-minute walking distance than at the start of the study.
Image
Gif_static_image
headline
content
disclaimer
content2
disclaimer2
Image_disclaimer
Brightcove_video_id
Brightcove_account_id
headline
Watch how VYNDAMAX can help you
video_id
6390808266112
account_id
1852113022001
title
poster
load
content
buttons
disclaimer
icon
headline
Create a discussion guide to help you log your symptoms and talk to your doctor about ATTR-CM
subheadline
content
disclaimer
buttons
eyebrow
headline
Cardiologist Recommended
headline2
VYNDAMAX is a treatment with a Class 1§ recommendation for ATTR-CM in guidelines from:
content
- American College of Cardiology
- American Heart Association
- Heart Failure Society of America
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer
§Class 1 guidelines are given when there’s strong evidence or general agreement that a treatment is beneficial, useful, and effective. The above recommendation is from the 2022 guidelines.
image
Mobile_image
eyebrow
headline
Hear from Stan, a real patient taking VYNDAMAX
subheadline
content
“I was glad to find out that there is treatment available now…so that gave me some hope.”
buttons
content2
disclaimer
Image_disclaimer
Brightcove_video_id
6372174251112
Brightcove_account_id
1852113022001
image
Mobile_image
eyebrow
headline
Get to the heart of what matters
subheadline
content
Stay informed with educational materials about ATTR-CM and VYNDAMAX.
buttons
content2
disclaimer
Image_disclaimer
Brightcove_video_id
Brightcove_account_id
eyebrow
headline
Explore how VYNDAMAX works
headline2
content
content2
buttons
Cta_brightcove_account_id
Cta_brightcove_video_id
disclaimer